Medium-chain fatty acid zinc, its preparation methods and applications

The synthesis of zinc hexanoate via a solvothermal method simplifies the process and reduces costs, solving the problems of complex synthesis and environmental pollution associated with medium-chain fatty acid zinc. This enables the application of an efficient and environmentally friendly antibiotic alternative, improving the growth performance and health of weaned piglets.

CN117447320BActive Publication Date: 2026-11-10HENAN UNIVERSITY OF TECHNOLOGY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311263304.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-09-27
Publication Date
2026-11-10
Estimated Expiration
2043-09-27

AI Technical Summary

Technical Problem

In existing technologies, the synthesis process of medium-chain fatty acid zinc is complex, costly, and environmentally unfriendly, making it difficult to meet the needs of industrial production. At the same time, the extensive use of antibiotics and zinc oxide leads to drug residues and environmental pollution problems.

Method used

Zinc hexanoate was synthesized by a solvothermal method. By controlling the molar ratio of hexanoic acid and zinc oxide and the amount of ethanol, the reaction was carried out under reflux, followed by recrystallization and vacuum distillation to obtain high-purity zinc hexanoate, which simplifies the process and reduces costs.

Benefits of technology

Obtaining high-purity zinc hexanoate significantly improved the treatment effect on diarrhea in weaned piglets, enhanced growth performance, and reduced the risk of environmental pollution.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117447320B_ABST
    Figure CN117447320B_ABST
Patent Text Reader

Abstract

This invention provides a medium-chain fatty acid zinc, its preparation method, and its application. The medium-chain fatty acid zinc is a white monoclinic zinc hexanoate, wherein hexanoic acid and zinc atoms are alternately linked to form a two-dimensional layered network. Zinc hexanoate exhibits significantly higher antibacterial effects than zinc oxide and hexanoic acid, and is stronger than commercially available zinc laurate. Within the limits stipulated by the Ministry of Agriculture and Rural Affairs, it treats diarrhea in weaned piglets and improves their growth performance, with effects exceeding those of pharmacological doses of zinc oxide. This invention also provides a method for preparing the aforementioned medium-chain fatty acid zinc, using hexanoic acid and zinc oxide as raw materials, and employing a solvothermal method for efficient synthesis of zinc hexanoate. This synthesis method features low cost and energy consumption, simple process, high raw material utilization, and environmental friendliness. This invention also provides the application of the aforementioned medium-chain fatty acid zinc in the preparation of drugs for treating diarrhea in weaned piglets or growth promoters for weaned piglets, as well as its application as an additive in feed preparation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to feed additives, and more particularly to a medium-chain fatty acid zinc, its preparation method, and its application. Background Technology

[0002] Diarrhea in weaned piglets has long been a difficult problem to solve in pig farming. Weaning stress and enterotoxigenic E. coli are among the important factors causing diarrhea in piglets. Adding antibiotics and high doses of zinc oxide to piglet diets has played a significant role in addressing this problem. However, the negative consequences of long-term, high-dose use of antibiotics and zinc oxide, such as drug residues, bacterial resistance, and environmental pollution, have attracted widespread public attention.

[0003] Studies have shown that medium-chain fatty acids (MCFAs) can improve the growth performance of piglets, improve protein metabolism, promote the absorption of nutrients in the intestines of weaned piglets, enhance animal immunity, and improve gut microbiota. Hexanoic acid, in particular, exhibits higher bioactivity than other MFAs. Zinc is considered an essential micronutrient for animals, playing multiple roles such as promoting growth, enhancing immunity, and promoting gut health. Consequently, alternatives to zinc oxide, such as inorganic zinc (nano zinc oxide, basic zinc chloride) and organic zinc (amino acid zinc, polysaccharide zinc, and some coated zinc products), have been extensively studied. Compared to inorganic zinc, organic zinc has higher bioavailability and can significantly promote piglet appetite, improve feed utilization, reduce diarrhea, and improve coat condition. Studies have shown that 200 ppm / kg of lysine zinc and 2500 ppm / kg of zinc oxide have comparable effects in improving the incidence of diarrhea and growth performance in weaned piglets. High-dose zinc oxide (2500–4000 mg / kg) is widely used in piglet production due to its effects in preventing diarrhea, enhancing immunity, and promoting growth. However, this dosage far exceeds the needs of piglets, and the excess zinc remains in their bodies or is excreted into the environment, causing pollution. Research on organic zinc is gradually becoming a hot research topic.

[0004] The synthesis of medium-chain fatty acid zinc mostly employs the saponification metathesis method. Xu Jiayou et al. (2010) synthesized zinc laurate using lauric acid, sodium hydroxide, and zinc chloride as raw materials under conditions of pH 5-6, constant temperature of 80℃, 10% excess sodium hydroxide, and 20% excess zinc chloride. However, the sample contained impurities such as lauric acid and zinc chloride, and the saponification metathesis synthesis process was complex, generating a large amount of industrial wastewater, which increased production costs due to wastewater treatment. Furthermore, the intermediate sodium laurate has a high gelling energy, easily encapsulating zinc chloride, resulting in low yield and quality, and low product solubility. Shi Shumin et al. (2021) developed a melt synthesis process for zinc laurate, adding lauric acid to a reactor and heating it to 80-160℃ to completely melt the lauric acid. Zinc oxide and a catalyst were then added, followed by stirring and spray granulation to obtain zinc laurate. However, this process is energy-intensive, has low yield and purity, and requires a catalyst, which cannot meet the needs of industrial production. Summary of the Invention

[0005] In view of this, the purpose of this invention is to provide a novel medium-chain fatty acid zinc, its preparation method and application. This novel medium-chain fatty acid zinc is zinc hexanoate, which can not only be used as a substitute for feed antibiotics and zinc oxide in the livestock industry to overcome the dilemma of banning antibiotics and restricting zinc, but also has the advantages of simple production process, green and environmentally friendly, low cost, industrial production capability and easy promotion and application.

[0006] Specifically, this invention provides a medium-chain zinc fatty acid, which is a white zinc hexanoate single crystal, monoclinic crystal system. Each zinc atom is coordinated with oxygen atoms from four different hexanoates to form a twisted tetrahedral configuration, and two of the molecular chains of the four hexanoates are parallel to each other, while the other two chains are at an angle of 69.481°. Each hexanoate molecule is connected to two tetrahedral coordinated zinc atoms through oxygen atoms in the carboxylic acid. Hexanoates and zinc atoms are alternately connected to form a two-dimensional layered network, wherein the zinc-oxygen tetrahedra and hexanoates are oriented in the same direction along the b-axis, and the zinc-oxygen tetrahedra and hexanoate ligands are arranged alternately up and down along the c-axis. The two-dimensional zinc hexanoate network is stacked in an interlaced spatial structure, and there is no obvious interaction between adjacent layers.

[0007] The present invention also provides a method for preparing the above-mentioned medium-chain fatty acid zinc, comprising: Synthesis of zinc hexanoate: Zinc hexanoate is synthesized from zinc oxide and excess hexanoic acid using a solvothermal method until the zinc oxide is completely reacted, resulting in a clear zinc hexanoate mixture. Crude extraction: The zinc acetate mixture is recrystallized to obtain crude zinc hexanoate; Refining process: Remove hexanoic acid from the crude zinc hexanoate and dry it to obtain pure zinc hexanoate.

[0008] The steps for synthesizing zinc hexanoate include: first mixing hexanoic acid and ethanol and then adding zinc oxide, or first dispersing zinc oxide in ethanol and then adding hexanoic acid to form a mixed raw material; the mixed raw material is refluxed with ethanol at 60℃~100℃ until the zinc oxide is completely reacted to obtain the zinc hexanoate mixture.

[0009] The molar ratio of hexanoic acid to zinc oxide is preferably greater than or equal to 3:1 to ensure that the zinc oxide reacts completely.

[0010] To ensure that zinc oxide reacts fully and is evenly dispersed, the molar ratio of ethanol to zinc oxide is preferably greater than or equal to 30:1 and less than or equal to 200:1.

[0011] The crude extraction process includes recrystallizing the zinc hexanoate mixture and then filtering it to obtain crude zinc hexanoate. The crude zinc hexanoate contains small amounts of hexanoic acid and ethanol. The recrystallization temperature is greater than or equal to -3°C, preferably room temperature greater than or equal to 0°C. In this crude extraction process, the filtrate obtained during recrystallization contains a large amount of hexanoic acid and ethanol. This filtrate can be used as a raw material and solvent for the synthesis of zinc hexanoate and can be recycled.

[0012] The refining process includes drying the crude zinc hexanoate to obtain pure zinc hexanoate. Since the hexanoic acid and ethanol contained in the crude zinc hexanoate are volatile substances, they can be removed by drying. Therefore, the drying temperature is preferably 55℃~80℃.

[0013] To further improve the purity of zinc hexanoate, the refining process may further include: dissolving the crude zinc hexanoate in ethanol and ultrasonically dispersing it, followed by multiple recrystallizations to remove excess hexanoic acid, obtaining a zinc hexanoate ethanol solution; subjecting the zinc hexanoate ethanol solution to vacuum distillation to remove ethanol, obtaining a zinc hexanoate semi-finished product; and freeze-drying the zinc hexanoate semi-finished product to obtain pure zinc hexanoate. The vacuum distillation temperature is greater than or equal to 50°C. During the refining process, the ethanol fraction collected during vacuum distillation is recycled as a solvent for the synthesis of zinc hexanoate.

[0014] Therefore, the zinc hexanoate provided by this invention uses hexanoic acid and zinc oxide as raw materials and is synthesized efficiently by a solvothermal method. This synthesis method has the characteristics of low cost and energy consumption, simple process, high raw material utilization and environmental friendliness.

[0015] This invention also provides the application of zinc hexanoate as an additive in the preparation of feed.

[0016] This invention also provides the application of zinc hexanoate in the preparation of a drug for treating diarrhea in weaned piglets.

[0017] This invention also provides the application of zinc hexanoate in the preparation of growth promoters for weaned piglets.

[0018] Experimental verification shows that the medium-chain fatty acid zinc hexanoate provided by this invention has a significantly higher antibacterial effect than zinc oxide and hexanoic acid, and is stronger than commercially available zinc laurate. It has treated diarrhea in weaned piglets within the limits stipulated by the Ministry of Agriculture and Rural Affairs, and improved the growth performance of weaned piglets. Moreover, the effect is higher than that of pharmacological doses of zinc oxide. Attached Figure Description

[0019] Figure 1 The images show the FTIR spectra of pure hexanoic acid (CA) and zinc hexanoate (ZnCA).

[0020] Figure 2 Figure A shows the SC-XRD spectrum of a single crystal of zinc hexanoate. In the figure, A represents the coordination environment of zinc, B represents the bridging mode of hexanoate, C represents the two-dimensional layered structure formed by hexanoate and zinc (C chain removed), D represents the two-dimensional structure formed by hexanoate and zinc, E represents the stacking of zinc hexanoate layers, and F represents a schematic diagram of the angle between the two Ch2 chains in Figure A.

[0021] Figure 3 For hexanoic acid and zinc hexanoate 1 H and 13 C NMR spectrum, where A: 1 H NMR spectrum, B: 13 C10 NMR spectrum.

[0022] Figure 4 SEM image of pure zinc hexanoate.

[0023] Figure 5 This is a particle size distribution diagram of pure zinc hexanoate.

[0024] Figure 6 The PXRD simulation spectrum of pure zinc hexanoate.

[0025] Figure 7 Figures show the results of the antibacterial performance study of zinc hexanoate against S. aureus and E. coli; where A: photograph of inhibition zone diameter; B: result of minimum inhibitory concentration determination; C: growth curve of E. coli; D: growth curve of S. aureus; E: result of antibacterial stability against E. coli; F: result of antibacterial stability against S. aureus.

[0026] Figure 8 SEM images of S. aureus and E. coli treated with zinc hexanoate.

[0027] Figure 9Figure 1 shows the results of a study on the antibacterial mechanism of zinc hexanoate against *E. coli* and *S. aureus*. A: Effect on biofilm formation in *E. coli* and *S. aureus*; B: Change in supernatant conductivity of *E. coli* cells over time; C: Change in supernatant conductivity of *S. aureus* cells over time; D: Effect on intracellular nucleic acid leakage in *E. coli* and *S. aureus* cells; E: Effect on protein leakage in *E. coli* and *S. aureus* cells; F: Effect on the inhibition of *Ca* in *E. coli* and *S. aureus* cells. 2+ Mg 2+ -Graph showing the results of ATPase activity assay.

[0028] Figure 10 The figure shows the results of zinc hexanoate assay for the cell membrane integrity of E. coli and S. aureus. Detailed Implementation

[0029] The technical solution of the present invention will be further described in detail below through specific embodiments. All reagents, materials, and other consumables used in the embodiments of the present invention are commercially available.

[0030] This invention provides a method for preparing white zinc hexanoate single crystals, mainly comprising the following steps: Synthesis of zinc hexanoate: Zinc hexanoate is synthesized from zinc oxide and excess hexanoic acid using a solvothermal method until the zinc oxide is completely reacted, resulting in a clear zinc hexanoate mixture. Crude extraction: The zinc acetate mixture is recrystallized to obtain crude zinc hexanoate; Refining process: Remove hexanoic acid from the crude zinc hexanoate and dry it to obtain pure zinc hexanoate.

[0031] The step of synthesizing zinc hexanoate may include: First, mix hexanoic acid and ethanol, then add zinc oxide to form a mixed raw material; or first, disperse zinc oxide in ethanol, then add hexanoic acid to form a mixed raw material. The mixed raw materials are refluxed in ethanol at 60℃~100℃ until the zinc oxide is completely reacted to obtain the zinc hexanoate mixture.

[0032] In the synthesis of zinc hexanoate, either mixing hexanoic acid and ethanol first, then adding zinc oxide for reflux reaction, or dispersing zinc oxide in ethanol first, then adding hexanoic acid for reflux reaction, can effectively avoid the zinc oxide being hindered from participating in the reaction by zinc hexanoate coating the zinc oxide surface. This promotes complete reaction of zinc oxide and reduces production costs. If zinc oxide is added first, then hexanoic acid, and finally ethanol, the zinc oxide surface will be coated with zinc hexanoate after the addition of hexanoic acid. After the reaction, white lumpy solids will not dissolve in ethanol, and the zinc oxide cannot be completely converted, affecting yield and production costs. If hexanoic acid is added first, then zinc oxide is added slowly, and finally ethanol is added, white spherical particles will appear, and the zinc oxide surface will still be coated with zinc hexanoate and clump together. After the reaction, the solution will be turbid, also affecting the yield and production cost of zinc hexanoate.

[0033] To ensure complete reaction of zinc oxide, the preferred molar ratio of hexanoic acid to zinc oxide is greater than or equal to 3:1, such as 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, etc. In this case, zinc oxide reacts completely, and the zinc hexanoate mixture becomes clear at the end of the reaction. When the molar ratio of hexanoic acid to zinc oxide is less than 3:1, zinc oxide cannot react completely, and the zinc hexanoate mixture becomes turbid at the end of the reaction, producing an insoluble precipitate, and it is difficult to purify and separate zinc hexanoate. For example, when the molar ratio of hexanoic acid to zinc oxide is 1:1 or 2:1, zinc oxide fails to react completely, and the zinc hexanoate mixture becomes turbid at the end of the reaction, producing an insoluble precipitate (due to the unreacted zinc oxide being insoluble in the solvent).

[0034] In the synthesis of zinc hexanoate, to ensure complete reaction and uniform dispersion of zinc oxide, the preferred molar ratio of ethanol to zinc oxide is greater than or equal to 30:1 and less than or equal to 200:1, such as 30:1, 40:1, 50:1, 60:1, 80:1, 100:1, 120:1, 140:1, 150:1, 160:1, 180:1, 200:1, etc. When the molar ratio of ethanol to zinc oxide is less than 30:1, such as 10:1, it is not conducive to the dispersion of zinc oxide, and zinc hexanoate coats the surface of zinc oxide, which is not conducive to the reaction. When the molar ratio of ethanol to zinc oxide is greater than 200:1, such as 250:1 or 300:1, zinc oxide fails to react completely, the solution becomes turbid, and a small amount of white precipitate appears at the bottom.

[0035] The crude extraction process includes: recrystallizing the zinc hexanoate mixture, followed by filtration to obtain crude zinc hexanoate and a filtrate. The crude zinc hexanoate contains small amounts of hexanoic acid and ethanol. In this crude extraction process, the filtrate contains large amounts of hexanoic acid and ethanol, and this filtrate can be used as a raw material for synthesizing zinc hexanoate and can be recycled.

[0036] The refining process includes drying the crude zinc hexanoate to obtain pure zinc hexanoate. Since the hexanoic acid and ethanol contained in the crude zinc hexanoate are volatile substances, they can be removed by drying. Therefore, the drying temperature is preferably 55℃~80℃, such as 55℃, 60℃, 65℃, 70℃, 75℃, 80℃, etc.

[0037] To further improve the purity of zinc hexanoate, the refining process includes: first, dissolving the crude zinc hexanoate in ethanol and ultrasonically dispersing it, followed by multiple recrystallizations to remove excess hexanoic acid, obtaining a zinc hexanoate ethanol solution; then, subjecting the zinc hexanoate ethanol solution to vacuum distillation to evaporate the ethanol solvent, removing the ethanol and obtaining a zinc hexanoate semi-finished product and collecting the ethanol fraction; finally, freeze-drying the zinc hexanoate semi-finished product to obtain pure zinc hexanoate. The collected ethanol fraction can be directly used as a solvent for the synthesis of zinc hexanoate, allowing for recycling.

[0038] According to experiments, the zinc hexanoate mixture requires 4 hours to completely recrystallize at 25°C and only 1 hour at 0°C. Since the melting point of hexanoic acid is -4°C, it is not conducive to the removal of hexanoic acid at -20°C. Therefore, the recrystallization temperature in both the crude extraction and refining steps is preferably -3°C to 30°C, such as -3°C, 0°C, 4°C, 5°C, 10°C, 15°C, 20°C, 25°C, 30°C, etc. More preferably, the recrystallization temperature is 0°C to 25°C.

[0039] Experiments showed that when ethanol was removed from the zinc hexanoate ethanol solution by vacuum distillation at 40℃, 50℃, and 60℃ for 1 h at a pressure of 0.083 MPa, the boiling points were 48.1℃ and 39℃ at vacuum pressures of 0.0737 MPa and 0.083 MPa, respectively. When the temperature was below 50℃, some ethanol remained. Therefore, the preferred vacuum distillation temperature is 50℃ to 70℃, such as 50℃, 55℃, 60℃, 65℃, and 70℃. Thus, this invention uses hexanoic acid and zinc oxide as raw materials to synthesize zinc hexanoate in one step using a reflux ethanol method. High-purity zinc hexanoate is synthesized in high yield by reacting hexanoic acid and zinc oxide in reflux ethanol. Excess free hexanoic acid is removed by ultrasonic treatment, ethanol is removed by vacuum distillation, and water is removed by freeze-drying, resulting in a pure zinc hexanoate product with a purity higher than 98%. The preparation process is simple and easy to promote and apply. Furthermore, ethanol and hexanoic acid can be recycled and reused, saving costs.

[0040] This invention also provides the application of zinc hexanoate as an additive in the preparation of feed.

[0041] This invention also provides the application of zinc hexanoate in the preparation of a drug for treating diarrhea in weaned piglets.

[0042] This invention also provides the application of zinc hexanoate in the preparation of growth promoters for weaned piglets.

[0043] Experiments have verified that the antibacterial effect of zinc hexanoate provided by this invention is significantly higher than that of zinc oxide and hexanoic acid, and stronger than that of commercially available zinc laurate. It has treated diarrhea in weaned piglets within the limits stipulated by the Ministry of Agriculture and Rural Affairs, and improved the growth performance of weaned piglets. Moreover, the effect is higher than that of pharmacological doses of zinc oxide.

[0044] The technical solution protected by this invention will be explained below with specific embodiments. Example 1 This embodiment provides a method for preparing zinc hexanoate, including the following steps: To synthesize zinc hexanoate, 500 mL of ethanol was added to 50.13 mL (0.4 mol) hexanoic acid, and 8.13 g (0.1 mol) of zinc oxide was added with slow stirring. Then, zeolite was added, and the mixture was refluxed with ethanol at 80 °C for about 15 min until the white precipitate at the bottom completely disappeared, the zinc oxide reacted completely, and the solution became completely clear, thus obtaining a mixed solution of zinc hexanoate. A colorless and transparent zinc hexanoate mixed solution was purified and recrystallized at 0℃ for 1 h, and then filtered to obtain crude zinc hexanoate. The prepared crude zinc hexanoate was added to ethanol and sonicated for 1 h, recrystallized at 0℃ for 1 h, and then filtered. This process was repeated three times to remove excess hexanoic acid, resulting in zinc hexanoate semi-finished product. The zinc hexanoate semi-finished product was first subjected to vacuum distillation at 0.085 MPa and 50℃ for 1 h to remove ethanol, and then freeze-dried for 36 h to remove water, yielding high-purity zinc hexanoate.

[0045] Structural characterization (1) FTIR 1–2 mg of zinc hexanoate sample was placed in an agate mortar, and 200 mg of potassium bromide powder was added. The mixture was thoroughly mixed and ground into a fine powder. The powder was then placed in a mold and pressed into a transparent sheet approximately 1 mm thick using a tablet press. The sheet was then scanned using a Fourier transform infrared spectrometer (Thermo Fisher Scientific, Niscolet IS 20). The scanning rate was 2 cm⁻¹, and the scanning range was 4000–400 cm⁻¹. -1 The bonding modes of hexanoic acid and zinc were characterized by comparing the FTIR spectra of hexanoic acid and zinc hexanoate. The results are as follows: Figure 1 As shown.

[0046] from Figure 1 It can be seen from this that: in hexanoic acid, the depth is 1703.54 cm. -1 The characteristic absorption peak of the carbonyl group at [location] is converted to that of zinc hexanoate at 1531.37 cm⁻¹. -1 Asymmetric stretching modes of the carboxyl group (υ) asym(COO-)) and at 1397.67 cm -1 Symmetrical stretching modes of the carboxyl group (υ) sym(COO-) ), in the range of 3500–2500 cm -1 The disappearance of the broad peaks of free carboxylic acid and hydroxyl groups in water confirms that the zinc hexanoate sample does not contain water molecules and that hexanoic acid has been deprotonated. Furthermore, infrared spectroscopy can be used to detect the disappearance of the broad peaks of free carboxylic acid and hydroxyl groups in water. asym(COO-) and υ sym(COO-) The bond vibrational difference determines the bonding mode between the hexanoic acid ligand and the zinc atom. Δ(υ asym(COO-) - υ sym(COO-) ) = 134 cm -1 This indicates that hexanoic acid coordinates zinc atoms through a bidentate bridging mechanism.

[0047] (2) SC-XRD Zinc hexanoate single crystals suitable for SC-XRD were cultured using a solvent evaporation method. Zinc hexanoate was dissolved in 50 mL of ethanol until supersaturated, sonicated for 1 h, and then filtered to obtain the supernatant. The supernatant was sealed with plastic wrap, punctured, and cultured at 0℃ for 24 h to obtain long, needle-shaped, colorless, and transparent crystals. Suitable-sized zinc hexanoate single crystals were fixed on a Bruker APEX-II CCD diffractometer, with the acquisition temperature maintained at 180 K, using graphite monochromatized Mo-Kα (λ = 0.71073 Å) as the radiation source. The structure was solved using the SHELXT structure solver with Olex2 and IntrinsicPhasing, and refined using the least-squares minimization SHELXL refinement package. The crystallographic data of zinc hexanoate are listed in Table 1, and some bond lengths and bond angles are listed in Tables 2 and 3, respectively.

[0048] Table 1. Crystallographic data and structural refinement parameters of zinc hexanoate Table 2. Partial bond lengths of zinc hexanoate 1 +X, 1-Y, -1 / 2+Z; 2 +X,1+Y, +Z Table 3. Partial bond angles of zinc hexanoate Crystallographic analysis indicates that zinc hexanoate is a monoclinic crystal with space group P1c1 (NO.7), and its structure is as follows: Figure 2 As shown, each zinc atom coordinates with oxygen atoms from four different hexanoic acids to form a distorted tetrahedral configuration. Figure 2A), and the two chains named Ch 1 are parallel to each other and located on the same side; the two chains named Ch 2 are located on the other side, and the planes containing the two Ch 2 chains intersect at an angle of 69.481°. Figure 2 F), each hexanoic acid molecule is connected to two tetrahedral zinc atoms via a carboxylic acid O atom bridge (F). Figure 2 B). Furthermore, as shown in Table 2, the two Zn-O bonds are of unequal length, indicating asymmetric bonding between zinc atoms and hexanoic acid, which is consistent with the FTIR results. Hexanoic acid and zinc atoms alternately connect to form a two-dimensional layered network, in which the zinc-oxygen tetrahedra and hexanoic acid are oriented in the same direction along the b-axis, while the zinc-oxygen tetrahedra and hexanoic acid ligands are arranged alternately vertically along the c-axis. Figure 2 C and 2D). Two-dimensional zinc hexanoate networks are staggered and stacked in a spatial structure, with no obvious interaction between layers (C and 2D). Figure 2 E).

[0049] (3) 1 H and 13 C NMR Five mg of hexanoic acid and zinc hexanoate samples were dissolved in deuterated dimethyl sulfoxide and then sonicated into an NMR tube. The NMR spectra of hexanoic acid and zinc hexanoate were measured using a Bruker AVANCE III HD 500 MHz NMR spectrometer (C and H spectroscopy). The results are as follows: Figure 3 As shown.

[0050] Depend on Figure 3 As shown in A, compared to hexanoic acid, the carboxyl H in zinc hexanoate disappears at 11.96 ppm, indicating the deprotonation of hexanoic acid. This also confirms the data in the FTIR, showing that hexanoic acid coordinates with zinc through the carboxyl group, further indicating that the zinc hexanoate sample does not contain free hexanoic acid. Figure 3 As shown in B, the resonance of the carboxyl carbon in hexanoic acid and zinc hexanoate is at 175 ppm and 179.46 ppm, respectively. The carboxyl carbon underwent a significant chemical shift, indicating a change in its electron cloud density, which also proves the binding of the carboxyl group with zinc.

[0051] (4) SEM A small amount of zinc hexanoate sample was placed in a centrifuge tube with an appropriate amount of water. After sonication at room temperature for 30 min, conductive adhesive was attached to the sample stage, and a clean thin copper sheet was attached to the conductive adhesive. The liquid sample was dropped onto the copper sheet in small amounts multiple times. After the solvent had completely evaporated and dried, gold was sputtered for 45 s using an Oxford Quorum SC7620 sputtering system with an electron beam of 5 mA as the target material. Subsequently, the sample morphology was photographed using a ZEISS GeminiSEM 300 scanning electron microscope at an accelerating voltage of 3 kV. The results are as follows. Figure 4 As shown, zinc hexanoate exhibits a layered structure, which is consistent with the results of SC-XRD single-crystal testing.

[0052] (5) Particle size analysis The particle size of pure zinc hexanoate was measured and analyzed using a Malvern laser particle size analyzer.

[0053] Measurements and analysis showed that zinc hexanoate had a radius of 1.758, a uniformity of 0.54, and a specific surface area of ​​5.81 m². 2 / g, the surface area average particle size D[3,2] is 1.033 μm, and the volume average particle size D[4,3] is 1.536 μm. The particle size distribution results are as follows: Figure 5 As shown, zinc hexanoate exhibits a single peak with d(0.1) of 0.547 μm, d(0.5) of 1.320 μm, and d(0.9) of 2.868 μm. The zinc hexanoate synthesized using this method shows good consistency and a concentrated particle size distribution.

[0054] (6) PXRD Powder X-ray diffraction analysis of the samples was performed using an Ultima III diffractometer. The operating conditions were: copper Kα radiation (λ = 1.5418 Å), scan rate of 1° / min, step size of 0.02°, operating power of 40 kV, 40 mA, and scanning at room temperature. The PXRD simulation pattern of zinc hexanoate was generated using single-crystal data of zinc hexanoate in Materials Studio 8.0 software. Figure 6 As shown.

[0055] from Figure 6 It can be seen that the positions of the main peaks in the experimental spectrum and the theoretical spectrum simulated by single crystal diffraction are basically consistent, indicating that the zinc hexanoate phase is relatively pure, which provides conditions for the study of the properties of zinc hexanoate and its development as a feed additive as an antibiotic alternative.

[0056] (7) Melting point determination The melting point of zinc hexanoate was tested using a WRS-2 digital melting point apparatus within the range of room temperature to 200℃. The result showed that the melting point of zinc hexanoate was 147.2℃, and the fixed melting point further demonstrates the high purity of the zinc hexanoate sample.

[0057] (8) Elemental analysis The C, H, and O elements in the sample were analyzed using an Elemantar Vario EL cube CHNS / O Series II elemental analyzer, and the results are shown in Table 4. The Zn element in zinc hexanoate was quantified according to the Chinese national standard GB / T 25865-2010 to assess the elemental composition of the sample. In simple terms, two drops of sulfuric acid solution (water:sulfuric acid = 1:1) were added to a 0.3 g ZnCA sample to dissolve it. Then, 50 mL of deionized water, 10 mL of ammonium fluoride solution (200 g / L), 2.5 mL of thiourea solution (100 g / L), and ascorbic acid (0.2 g) were added sequentially. After shaking to dissolve, 15 mL of acetate-sodium acetate buffer solution (pH = 5.5) and 3 drops of xylenol orange indicator solution (2 g / L) were added. The titration was performed with 0.05 mol / L disodium ethylenediaminetetraacetate standard titration solution. The endpoint was reached when the solution changed from red to bright yellow.

[0058] Table 4. Elemental analysis results of zinc hexanoate Based on the zinc content and the aforementioned “(6) PXRD” and “(7) melting point determination”, the purity of the zinc hexanoate sample is estimated to be above 98%.

[0059] Performance verification 1. Study on the antibacterial activity and mechanism of zinc hexanoate against *Staphylococcus aureus* (CICC AB91093) and *Escherichia coli* (O149:K91:K88ac). 1.1 Preparation of bacterial suspension Glycerol tubes containing standard strains of *S. aureus* and *E. coli* were rapidly thawed in a 37 °C water bath for 1 min. They were then inoculated into LB liquid medium and incubated with shaking at 37 °C for 24 h at 180 r / min. The test strains were then streaked onto LB solid medium (main components: 10 g / L tryptone, 5 g / L yeast extract, 10 g / L sodium chloride, agar) and incubated at 37 °C for 24 h. Single typical colonies were then picked and propagated in LB liquid medium. The bacterial concentration of each bacterium was calculated using the dilution plating method, with the final dilution concentration being 10-1. 7 CFU / mL.

[0060] 1.2 Preparation of antibacterial solution Weigh out 30 μmol / mL hexanoic acid (CA), 15 μmol / mL zinc sulfate, 15 μmol / mL zinc oxide, and 15 μmol / mL zinc hexanoate (ZnCA) and dissolve them in LB liquid medium (main components: 10 g / L tryptone, 5 g / L yeast extract, 10 g / L sodium chloride) containing 1.5% ethanol and 1.5% Tween-80, and mix thoroughly. The 1.5% ethanol and 1.5% Tween-80 were used as solvents, and preliminary experiments showed that these solvents had no inhibitory activity against *S. aureus* and *E. coli*.

[0061] 1.3 Determination of inhibition zone diameter (DIZ) The antibacterial activity of zinc hexanoate was evaluated qualitatively by measuring the DIZ (Dispersive Inhibitor) activity of different substances against *E. coli* and *S. aureus*. Specifically, the Oxford cup method was used to determine the antibacterial activity of sterile aqueous solutions of 30 μmol / mL hexanoic acid (CA), 15 μmol / mL zinc sulfate, 15 μmol / mL zinc oxide, and 15 μmol / mL zinc hexanoate (ZnCA) against *S. aureus* and *E. coli*. Under aseptic conditions, 200 mL of autoclaved LB solid medium was cooled to 50°C, and 2 mL of bacterial suspension (1.1 Preparation of Bacterial Suspension) was added. The mixture was shaken and mixed, and then poured into glass petri dishes (d = 9 cm) containing three Oxford cups (d = 6 mm) and allowed to stand (25 mL added to each petri dish). After the medium solidified, the Oxford cups were removed, and 150 μL of the test solution was injected into the corresponding wells. Equal volumes of solvent (1.5% ethanol + 1.5% Tween-80) and 1 mg / mL ampicillin were used as negative and positive controls, respectively. The culture dishes were incubated at 37℃ for 24 h, and the diameter of the inhibition zone was measured using the cross-sectional method. The experiment was independently repeated three times, and the average value was taken as the result. Results are as follows... Figure 7 As shown in A and 7B.

[0062] Depend on Figure 7 As shown in A and 7B, zinc oxide did not exhibit antibacterial activity against E. coli and S. aureus; the inhibition zone diameters of hexanoic acid, zinc hexanoate, and zinc sulfate against E. coli were 9.73 ± 0.16 mm, respectively. b 12.39 ±0.15 a and 12.12±0.09 a The inhibition zone diameter against *S. aureus* was 10.29 ± 0.22 mm. c 14.00 ±0.09 a and 13.44 ± 0.12 bHexanoic acid and zinc hexanoate showed strong antibacterial effects against Staphylococcus aureus, but weaker effects against Escherichia coli. The inhibition zone diameter of zinc hexanoate against E. coli was significantly larger than that of hexanoic acid (P=0.001) and larger than that of ZnSO4, but the difference was not statistically significant (P=0.106). For S. aureus, the inhibition zone diameter of zinc hexanoate was also significantly larger than that of hexanoic acid (P<0.001) and zinc sulfate (P<0.05). The preliminary results of the inhibition zone determination indicate that zinc hexanoate has antibacterial effects against both E. coli and S. aureus, and its antibacterial effect is significantly stronger than that of hexanoic acid.

[0063] 1.4 Determination of Minimum Inhibitory Concentration (MIC) S. aureus and E. coli were inoculated into LB liquid medium and cultured at 37°C and 180 r / min until the logarithmic growth phase. Cells were then collected and configured into 10⁻⁶ cells / mL. 6 CFU / mL bacterial suspensions were mixed thoroughly with zinc hexanoate at concentrations of 295.6, 443.4, 591.2, 665.1, 739, and 886.8 μg / mL, and zinc laurate at concentrations of 250, 500, 1000, 2000, and 4000 μg / mL, respectively. An equal volume of LB liquid medium served as a negative control, and an equal volume of 0.1 mg / mL ampicillin served as a positive control. The cultures were incubated at 37℃ and 180 rpm for 24 h. The OD600 nm of each tube was measured at 0 and 24 h. The minimum concentrations of zinc hexanoate and zinc laurate corresponding to no bacterial growth (no change in OD600 nm) were defined as the minimum inhibitory concentrations (MICs). The results are shown in Tables 5 and 6.

[0064] Table 5. Determination of MIC of zinc hexanoate for E. coli and S. aureus Table 6. Determination of the MIC of zinc laurate on E. coli and S. aureus Under the experimental conditions, the MIC values ​​of zinc hexanoate against *E. coli* and *S. aureus* were 665.1 and 591.2 μg / mL, respectively (as shown in Table 5). Zinc hexanoate was more effective against *S. aureus* than against *E. coli*, which is consistent with the results of the DIZ assay. The results of the DIZ and MIC assays indicate that zinc hexanoate has a slightly stronger antibacterial effect against *S. aureus* than against *E. coli*.

[0065] Furthermore, the MIC of zinc hexanoate against E. coli (665.1 μg / mL) was higher than that of zinc laurate (2000 μg / mL), while the MIC of zinc hexanoate against S. aureus (591.2 μg / mL) was the same as that of laurate (1000 μg / mL).

[0066] 1.5 Treatment of bacterial cells S. aureus and E. coli were cultured to the logarithmic growth phase, with the bacterial culture volume added at 1% of the total solution volume. Pure zinc hexanoate was added to achieve final concentrations of 0.5 MIC and 1 MIC, respectively. An equal volume of LB liquid medium containing 1.5% anhydrous ethanol and 1.5% Tween-80 was used as a blank control group. All cultures were incubated in a constant temperature shaker at 37℃ and 180 r / min.

[0067] 1.6 Determination of growth curve Samples of the bacterial cells treated with "1.5% bacterial cells" were taken at 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 h, and the OD600 nm value was measured. Growth curves were plotted using the incubation time and OD600 nm values ​​to detect the changes in the growth curves of *S. aureus* and *E. coli* affected by zinc hexanoate. The results are as follows: Figure 7 As shown in C and D.

[0068] from Figure 7 As shown in C and D, the growth of the two pathogenic bacteria went through three distinct phases: the delayed phase, the logarithmic growth phase, and the stationary phase. Both *S. aureus* and *E. coli* entered the logarithmic growth phase after 2 hours, continued for 8 hours, entered the stationary phase, and reached their peak at 24 hours. When 0.5 MIC of zinc hexanoate was added, bacterial growth slowed, and the OD600 nm values ​​of *S. aureus* and *E. coli* decreased by 68.85% (2 hours) and 62.12% (4 hours), respectively, compared to the blank control group. When the zinc hexanoate concentration reached the MIC, the OD600 nm values ​​of *S. aureus* and *E. coli* decreased by 95.56% (12 hours) and 94.31% (14 hours), respectively, compared to the blank control group. The lack of significant change in the OD600 nm values ​​of the two bacteria indicates that the growth of *S. aureus* and *E. coli* was completely inhibited.

[0069] 1.7 Determination of antibacterial stability The OD600 nm values ​​of the culture medium of the cells treated with "1.5 cells" were measured at 12, 24, 36, 48, 60, and 72 hours, respectively. The results are as follows: Figure 7 As shown in E and F. The inhibition rate is calculated using the following formula: IC ((%)) = [(At, n − A0, n) − (At, s − A0, s)] / (At, n − A0, n) × 100% Where A0, n is the OD600 nm of the control group at the beginning; At, n is the OD600 nm of the control group at a specific time; A0, s is the OD600 nm of the experimental sample at the beginning; At, s is the OD600 nm of the experimental sample at a specific time.

[0070] Depend on Figure 7 As shown in E and F, after continuous sampling and testing of both bacteria after culture, the antibacterial stability of zinc hexanoate against *E. coli* was basically similar to that against *S. aureu*. Within the first 36 hours, the inhibition rate of zinc hexanoate against both *E. coli* and *S. aureu* was above 99%; at 72 hours, the inhibition rate of zinc hexanoate against both *E. coli* and *S. aureu* was still above 90%. Therefore, zinc hexanoate has an inhibitory effect on both *E. coli* and *S. aureu* within 72 hours.

[0071] 1.8 Observation of bacterial cell morphology The morphological changes of the two tested bacterial strains after treatment with zinc hexanoate (1×MIC) for 24 h were observed by SEM to preliminarily explore the antibacterial mechanism of zinc hexanoate. The SEM results are as follows: Figure 8 As shown.

[0072] Bacterial cells treated with "1.5 cells" were sampled after 12 h. After sampling, the cells were collected by centrifugation and fixed with 2.5% glutaraldehyde at 4℃ in the dark for 12 h. The samples were then dehydrated with different concentrations of ethanol-water solutions at concentration gradients of 30%, 50%, 70%, 80%, and 90%, and dehydrated twice with 100% ethanol. The dehydration was then repeated once with ethanol:tert-butanol (2:1, 1:1) and once with 100% tert-butanol. Finally, a suitable concentration of bacterial-tert-butanol suspension was dropped onto aluminum foil, pre-cooled to -80℃, and then freeze-dried. The dried samples were fixed on aluminum foil and sputtered with gold. The bacterial morphology was observed and photographed using a scanning electron microscope.

[0073] from Figure 8It can be seen that the cell membranes of *E. coli* without zinc hexanoate treatment are neat, smooth, and dense, with intact rod-like structures, exhibiting uniform long-chain rod shapes. However, after zinc hexanoate treatment, the cell membranes of *E. coli* show obvious shape abnormalities, becoming irregular, concave, ruptured, and wrinkled. Similarly, zinc hexanoate also affects the cell morphology of *S. aureu*. Untreated *S. aureu* cells are round and plump with smooth and intact surfaces; while treated *S. aureu* cells are severely damaged, with rough and wrinkled cell membrane surfaces, short cells, blurred outlines, and some cells showing cavities and ruptures, with bacterial contents leaking out.

[0074] 1.9 Determination of biofilm formation The effect of zinc hexanoate on biofilm formation in *S. aureus* and *E. coli* was determined using crystal violet staining. The results are as follows: Figure 9 As shown in Figure A.

[0075] After culturing the cells treated with "1.5 cells" for 0, 2, 4, 6, 8, and 10 h, the culture medium was aspirated, and the cells were washed three times with sterile PBS. Then, 200 μL of 0.1% (w / v) crystal violet was added for staining for 30 min, followed by washing with sterile PBS. Finally, the cells were destained with 200 μL of 95% ethanol, and the absorbance at 595 nm was measured using a microplate reader.

[0076] from Figure 9 As shown in Figure A, zinc hexanoate treatment significantly inhibited biofilm formation in both *E. coli* and *S. aureus* at concentrations of 0.5 MIC and MIC. Furthermore, biofilm formation in both *E. coli* and *S. aureus* decreased with increasing zinc hexanoate concentration. These biofilm formation results indicate that zinc hexanoate significantly inhibits biofilm formation in both *E. coli* and *S. aureus*.

[0077] 1.10 Determination of cell membrane permeability 1) Bacterial cells treated with "1.5 bacterial cells" (LB medium replaced with sterile water) were sampled at 0, 2, 4, 6, 8, and 10 h and centrifuged at 4℃ and 5000 r / min for 15 min. The conductivity of the supernatant was measured as L2. The conductivity of the 0.5 MIC and MIC concentration inhibitory solutions was measured after centrifugation as L1. The blank control was boiled for 10 min, centrifuged, and the conductivity of the supernatant was measured as L0. The experiment was repeated three times. The results are as follows: Figure 9 As shown in BC. Relative conductivity is calculated using the formula: Relative conductivity (%) = (L2-L1) / L0×100.

[0078] from Figure 9The BC assay showed that the relative conductivity of both *E. coli* and *S. aureus* treated with MIC zinc hexanoate increased significantly over time, and was significantly higher than that of strains treated with 0.5 MIC zinc hexanoate. At 10 h, *E. coli* treated with 0.5 MIC and MIC zinc hexanoate showed increases of 41.42% and 65.93%, respectively, compared to the control group; similarly, *S. aureus* treated with 0.5 MIC and MIC zinc hexanoate showed increases of 72.37% and 80.65%, respectively, compared to the control group. Therefore, it is speculated that zinc hexanoate can alter the permeability of the cell membranes of *E. coli* and *S. aureus*, causing extravasation of intracellular electrolytes and thus increasing the conductivity of the culture medium.

[0079] 2) After 10 h of treatment with "1.5 bacterial cells" (LB medium replaced with PBS buffer), the bacterial cells were collected by centrifugation at 8000 g for 5 min at 4℃. 3 mL of the supernatant was collected and filtered through a 0.22 μm filter membrane. The OD260 and OD280 of the supernatant were measured using a UV-Vis spectrophotometer after filtration. The results are as follows: Figure 9 As shown in DE.

[0080] Figure 9 Figure D shows the effect of zinc hexanoate on intracellular nucleic acid leakage in E. coli and S. aureus cells. For E. coli, at 10 h, the OD260 values ​​of the zinc hexanoate 0.5 MIC and MIC concentration treatment groups were 1.89 and 2.71 times that of the control group, respectively; similarly, for S. aureus, the OD260 values ​​of the 0.5 MIC and MIC zinc hexanoate groups were 3.15 and 4.16 times that of the control group, respectively.

[0081] Figure 9 E is a graph showing the effect of zinc hexanoate on intracellular protein leakage in E. coli and S. aureus cells. Consistent with the results on nucleic acid leakage, the OD280 of 0.5 MIC and MIC MIC zinc hexanoate were 2.29 and 3.74 (E. coli) and 4.83 and 8.04 (S. aureus) for the control group, respectively. The results also indicate that the amount of intracellular biomolecule leakage in E. coli and S. aureus caused by zinc hexanoate is positively correlated with the zinc hexanoate dose.

[0082] 1.11 Ca 2+ Mg 2+ Assay for ATPase activity After 12 h of treatment with "1.5 bacterial cells" (LB medium replaced with physiological saline), the bacterial cells were collected by centrifugation at 8000 g for 5 min at 4°C. The cells were then homogenized at 8000 rpm / min for 3 min, followed by ultra-micro Ca... 2+-Mg 2+ - ATPase test kit (Nanjing Jiancheng, China) measures the Ca2+ of 0, 0.5 MIC and MIC-treated Escherichia coli and Staphylococcus aureus. 2+ Mg 2+ -ATPase activity, results as follows Figure 9 As shown in F.

[0083] from Figure 9 F shows that after 12 h of zinc hexanoate treatment, the Ca2+ levels in the control group were significantly lower than those in E. coli and S. aureus. 2+ -Mg 2+ The ATPase activities of *E. coli* and *S. aureus* treated with 0.5 MIC zinc hexanoate were 6.49±0.24 and 6.85±0.20 U / mgprot, respectively. The ATPase activities of *E. coli* and *S. aureus* treated with 0.5 MIC zinc hexanoate were 3.79±0.39 and 3.03±0.02 U / mgprot, respectively, which were half the ATPase activities of the control group. The ATPase activities of *E. coli* and *S. aureus* treated with MIC zinc hexanoate were 0.08±0.03 and 0.11±0.01, respectively, a decrease of more than 60-fold. Furthermore, with increasing zinc hexanoate concentration, Ca... 2+ -Mg 2+ -ATPase activity was significantly reduced (P<0.05).

[0084] 1.12 Determination of cell membrane integrity SYTO 9 can label all bacteria within a colony (both with intact and damaged membranes), while PI can only penetrate damaged membranes. Furthermore, PI insertion causes a decrease in SYTO 9 staining fluorescence. When both dyes are added to the system, bacteria with intact membrane structures exhibit green fluorescence, while bacteria with damaged membrane structures exhibit red fluorescence. In this study, *Escherichia coli* and *Staphylococcus aureus* were treated with zinc hexanoate at concentrations of 0, 0.5 MIC, and MIC and stained with SYTO 9 and PI, and the results are as follows: Figure 10 As shown.

[0085] The specific method was as follows: After 4 h of treatment with 1.5 μL of cells (LB medium replaced with PBS), the cells were washed and fixed with 4% paraformaldehyde for 30 min at room temperature. They were then washed twice with cold PBS, and 1.5 μL of propidium iodide and 1.5 μL of SYTO9 were added. The cells were incubated at 37°C in the dark for 30 min. The cells were then seeded onto a glass slide, covered with a coverslip, and observed under a fluorescence microscope. Fluorescence images were recorded. The excitation / emission wavelengths (exi / emi) of SYTO9 and PI fluorophores were 480 nm / 500 nm and 490 nm / 635 nm, respectively. The combined image was taken at the exi / emi values ​​of 490 / 635 nm.

[0086] Depend on Figure 10 It can be seen that SYTO 9 / PI staining showed that most of the E. coli and S. aureus control group were stained only green fluorescence, indicating that the control group had a higher density of viable cells and intact cell membranes. E. coli and S. aureus treated with zinc hexanoate at 0.5 MIC showed more cells with damaged cell membranes than the control group. In E. coli and S. aureus treated with zinc hexanoate at MIC, the cell membranes of most bacteria were damaged, exhibiting red fluorescence, with only a small number of cells showing green fluorescence. The results indicate that the higher the concentration of zinc hexanoate, the more severe the damage to the cell membrane integrity of E. coli and S. aureus.

[0087] 2. Effects of zinc hexanoate on diarrhea in weaned piglets challenged with Escherichia coli K88 (1) Experimental scheme Forty-eight healthy Duroc × Landrace × Large White castrated weaned piglets (21 days old, 6.5 kg) were randomly divided into four groups, with six replicates per group and two piglets per replicate. The four treatments were: control group (basal diet, CON), negative control group (basal diet + K88 challenge, NC), positive control group (2500 mg / kg ZnO + K88 challenge, PC), and zinc hexanoate group (1500 mg / kg ZnCA + K88 challenge, ZnCA).

[0088] The experiment lasted 19 days, with 3×10⁻⁶ doses administered on day 8. 10 Piglets were challenged with ETEC K88 at CFU / mL. To ensure a full stomach at the time of inoculation and facilitate bacterial colonization, feeding was stopped at 21:00 the day before inoculation and resumed 30 minutes before inoculation. This challenge was repeated for three consecutive days to establish a model of intestinal inflammation and diarrhea in piglets.

[0089] The feeding trial was conducted from June 13 to July 5, 2023, at the Animal Experiment Base of Henan Agricultural University in Xuchang. Each experimental group was fed at 8:00, 11:00, 14:00, and 17:00 daily, with free access to feed and water. Daily management and disease prevention were carried out according to the standard procedures of a pig farm.

[0090] (2) Sampling scheme On days 0 and 14 after the start of the formal experiment, each piglet was weighed before morning feeding, and its weight was recorded. Feed intake was recorded daily by pen. Average daily gain (ADG), average daily feed intake (ADFI), and feed conversion ratio (FCR) were calculated. During the experiment, the diarrhea severity scoring criteria are shown in Table 7, and rectal temperature was measured. The daily average diarrhea score for each replicate was then calculated. The results are shown in Table 8.

[0091] Table 7 Scoring Criteria for Diarrhea Status Scoring Criteria Diarrhea score Normal, solid stool 0 Moist feces, semi-solid, slightly soft feces 1 Mild diarrhea, pasty stools 2 Severe diarrhea, watery stools 3 Table 8 Effects of zinc hexanoate on growth performance and diarrhea scores in ETEC-challenged weaned piglets Table 8 shows that the ADG in the zinc hexanoate group was significantly higher than that in the blank group and the negative control group, but not significantly different from that in the positive control group. There was no significant difference in ADFI among the four treatment groups. Regarding FCR, the zinc hexanoate group showed no significant difference compared to the blank group and the positive control group, but significantly reduced the FCR of weaned piglets compared to the negative control group. Furthermore, the average diarrhea scores in the zinc hexanoate group and the positive control group were not significantly different from those in the blank group, but significantly lower than those in the negative control group. These results indicate that zinc hexanoate can increase ADG, reduce FCR, and effectively alleviate diarrhea in weaned piglets challenged with ETEC, with effects superior to 2500 mg / kg ZnO.

[0092] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and not to limit them; although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications can still be made to the specific implementation of the present invention or equivalent substitutions can be made to some technical features without departing from the spirit of the technical solutions of the present invention, and all such modifications and substitutions should be covered within the scope of the technical solutions claimed in the present invention.

Claims

1. The application of zinc hexanoate in the preparation of a drug for treating diarrhea in weaned piglets.

2. The application according to claim 1, characterized in that, Zinc hexanoate is a white single crystal of zinc hexanoate, monoclinic crystal system, space group [space group missing]. P 1 c 1. Cell parameters include: a =16.353 Å b =4.7553 Å c =9.2278 Å α =90° β =103.656° γ =90°, unit cell volume = 697.31 Å 3 Each zinc atom coordinates with oxygen atoms from four different hexanoic acids to form a twisted tetrahedral configuration, with two chains of the four hexanoic acid molecules being parallel to each other and the other two chains forming an angle of 69.481°. Each hexanoic acid molecule is connected to two tetrahedral zinc atoms through oxygen atoms in the carboxylic acid. Hexanoic acid and zinc atoms are alternately connected to form a two-dimensional layered network, in which the zinc-oxygen tetrahedra and hexanoic acid are oriented in the same direction along the b-axis, and the zinc-oxygen tetrahedra and hexanoic acid ligands are arranged alternately up and down along the c-axis. The two-dimensional zinc hexanoate network is stacked in an interlaced spatial structure, with no obvious interaction between adjacent layers.

3. The application according to claim 1 or 2, characterized in that, The preparation method of zinc hexanoate includes the following steps: Synthesis of zinc hexanoate: Zinc hexanoate is synthesized from zinc oxide and excess hexanoic acid using a solvothermal method until the zinc oxide is completely reacted, resulting in a clear zinc hexanoate mixture. Crude extraction process: The zinc hexanoate mixture is recrystallized to obtain crude zinc hexanoate; Refining process: Remove hexanoic acid from the crude zinc hexanoate and dry it to obtain pure zinc hexanoate.

4. The application according to claim 3, characterized in that, The steps for synthesizing zinc hexanoate include: first mixing hexanoic acid and ethanol and then adding zinc oxide, or first dispersing zinc oxide in ethanol and then adding hexanoic acid to form a mixed raw material; the mixed raw material is refluxed with ethanol at 60℃~100℃ until the zinc oxide is completely reacted to obtain the zinc hexanoate mixture; wherein, the molar ratio of hexanoic acid to zinc oxide is greater than or equal to 3:

1.

5. The application according to claim 4, characterized in that, The molar ratio of ethanol to zinc oxide is greater than or equal to 30:1 and less than or equal to 200:

1.

6. The application according to claim 3, characterized in that, The crude extraction process includes: recrystallizing the zinc hexanoate mixture and then filtering it to obtain crude zinc hexanoate; wherein the recrystallization temperature is -3℃ to 30℃.

7. The application according to any one of claims 4 to 6, characterized in that, The refining process includes drying the crude zinc hexanoate to obtain pure zinc hexanoate; wherein the drying temperature is 55℃~80℃.

8. The application according to any one of claims 4 to 6, characterized in that, The refining process further includes: dissolving the crude zinc hexanoate in ethanol and dispersing it ultrasonically, then recrystallizing it multiple times to remove excess hexanoic acid and obtain a zinc hexanoate ethanol solution; subjecting the zinc hexanoate ethanol solution to vacuum distillation to remove the ethanol solvent and obtain a zinc hexanoate semi-finished product; and freeze-drying the zinc hexanoate semi-finished product to obtain pure zinc hexanoate; wherein the vacuum distillation temperature is 50℃~70℃.

9. The application according to claim 8, characterized in that, The ethanol fraction collected during the vacuum distillation process is recycled as a solvent for the synthesis of zinc hexanoate.

10. The application according to any one of claims 4 to 6, characterized in that, The filtrate obtained in the recrystallization process contains hexanoic acid and ethanol, which are recycled as raw materials and solvents for the synthesis of zinc hexanoate.